INTRODUCTION
============

The tumor suppressor p53 is a transcription factor that responds to various types of cellular stress, including DNA damage and oncogene activation. p53 regulates the expression of genes involved in a variety of cellular functions, including cell cycle arrest, DNA repair and apoptosis ([@gkt222-B1; @gkt222-B2; @gkt222-B3]). Abnormalities in the p53 pathway are found in nearly all types of cancers, and *p53* mutations are often associated with aggressiveness of tumor and poor patient prognosis ([@gkt222-B4]). To date, ∼180 human genes have been experimentally confirmed as p53 targets ([@gkt222-B5]).

MicroRNAs (miRNAs) are a class of short (21--25 nucleotides), single-stranded, non-coding RNAs. They bind to the 3′-untranslated regions (3′-UTRs) or protein-coding exons of specific mRNAs and inhibit translation or promote degradation of the transcript ([@gkt222-B6]). Repression of miRNA biogenesis by suppression of the key components of miRNA processing machinery, such as Drosha and Dicer, promotes cellular transformation and tumorigenesis ([@gkt222-B7]). This suggests that miRNAs might have intrinsic functions in tumor suppression and their down-regulation may accelerate oncogenesis. Recent studies have demonstrated a direct connection between p53 tumor suppressor networks and miRNA biogenesis machinery ([@gkt222-B8; @gkt222-B9; @gkt222-B10; @gkt222-B11; @gkt222-B12]). This suggests that *p53* mutations can down-regulate transcription and processing of miRNAs in human cancers. The miRNA *let-7* functions as a tumor suppressor by targeting multiple oncogenes, and a reduction of *let-7* levels is strongly associated with increased tumorigenicity and poor patient prognosis ([@gkt222-B13]). Recently, Lin28 proteins have been identified as regulatory factors for *let-7* biogenesis ([@gkt222-B14],[@gkt222-B15]). In human tumors, Lin28 is up-regulated and reactivated to function as an oncogene promoting malignant transformation and tumor progression ([@gkt222-B16]). Thus, down-regulation of Lin28 in tumors that overexpress this gene may provide a means to reactivate expression of the *let-7* tumor suppressor ([@gkt222-B16]).

Post-transcriptional regulation of gene expression can be mediated by AU-rich elements (AREs) located in the 3′-UTR of a variety of short-lived mRNAs such as cytokines and proto-oncogenes ([@gkt222-B17]). The destabilizing function of AREs is regulated by ARE-binding proteins ([@gkt222-B18]). One of the best-characterized ARE-binding proteins is tristetraprolin (TTP), which promotes degradation of ARE-containing transcripts ([@gkt222-B19],[@gkt222-B20]). Previously, we have reported that *Lin28a* mRNA contains AREs within the 3′-UTR, and TTP acts as a positive regulator of *let-7* biogenesis by down-regulating *Lin28a* expression in human cancer cells ([@gkt222-B21]). However, TTP expression was shown to be significantly decreased in various cancers ([@gkt222-B22]), which correlates with reduced expression of *let-7* ([@gkt222-B13]) and, as a result, may lead to abnormalities that contribute to cancer processes. Therefore, understanding the mechanisms that regulate TTP levels in cancer cells may provide new insights for controlling of the expression of oncogenes and the *let-7* tumor suppressor.

We show here for the first time that p53 stimulated by the genotoxic agent doxorubicin (DOX) induced the expression of *TTP* in human cancer cells. This induction led to an increase in *let-7* levels through down-regulation of *Lin28a*, a negative regulator of *let-7*. These studies thus represent a novel signaling pathway by which TTP complements p53 function through down-regulation of oncogenes and induction of *let-7*. These novel findings suggest that p53 serves as a positive regulator of both *TTP* and *let-7* expression and provides a mechanism for the widespread decrease in TTP and *let-7* observed in human cancers.

MATERIALS AND METHODS
=====================

Patients
--------

Tissue samples were obtained from 45 patients with colonic adenocarcinoma who underwent surgical treatment at the Ulsan University Hospital during 2006 and 2007. Forty-eight samples of normal colonic mucosa were taken from tissues distant from the tumors. Tissue samples were fixed with 10% neutral formalin and embedded in paraffin. The Local Ethical Committee of Ulsan University Hospital approved this work.

Plasmids, small interfering RNAs, transfections and dual-luciferase assay
-------------------------------------------------------------------------

The pcDNA6/V5-TTP and the psiCHECK/Lin28a 3′-UTR ([@gkt222-B21]) constructs were described previously. The pcDNA3/Flag-Lin28a construct was a gift from Dr. V. Narry Kim (Seoul National University, Seoul, Korea). pCMV-p53WT (containing human wild-type p53) and pCMV-p53MUT (human p53 mutant) constructs were purchased from Clontech (631922), and pGL3 basic and pRL-SV40 from Promega (E2231).

Small interfering RNAs (siRNAs) against human *TTP* (TTP-siRNA, sc-36761), human *Lin28a* (Lin28a-siRNA, sc-106829), human *p53* (p53-siRNA, sc-29435) and control siRNA \[scrambled siRNA (scRNA), sc-37007\] were purchased from Santa Cruz Biotechnology (Santa Cruz). Cells were transfected at 24 h after plating using Lipofectamine™ RNAiMAX (Invitrogen) and were harvested at 48 h. The expression levels of *TTP, p53* or *Lin28* mRNA and protein were analyzed by RT-PCR and western blots. To monitor transfection efficiency, the GFP expression vector pEGFP-N1 (Clontech) was co-transfected with the plasmid construct or each oligonucleotide. After confirming transfection efficiency (\>80%), cells were used for further study.

The sequence of the human *TTP* genomic locus at 19q13.1 (GenBank accession number NC_000019.9) was used to design PCR cloning primers. A 1411-bp genomic fragment containing the 5′-flanking region of the TTP gene was isolated by PCR amplification from human genomic DNA. Detailed procedures for generation of deletion and point mutants can be found in [Supplemental Experimental Procedures](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1).

For luciferase assays, cells were co-transfected with pGL3/TTPp-1343-luciferase reporter construct, pCMV-p53WT or pCMV-p53MUT (Clontech) and pRL-SV40 Renilla luciferase construct using TurboFect™ *in vitro* transfection reagent (Fermentas). Transfected cells were lysed with lysis buffer and mixed with luciferase assay reagent (Promega), and the chemiluminescent signal was measured in a SpectraMax L Microplate (Molecular Devices, Sunnyvale, CA). Firefly luciferase was normalized to Renilla luciferase in each sample. All luciferase assays reported here represent at least three independent experiments, each consisting of three wells per transfection.

Electrophoretic mobility shift assay
------------------------------------

Nuclear extracts of PA1 cells were prepared with the NE-PER nuclear extraction reagent (Pierce). Biotin end-labeled double-stranded oligonucleotides (hTTP-p53RE-134 WT, 5′-CGGAAGGGAACCAGTCCAGGGCCAGCCAGGCTGCGCCGG-3′; hTTP-p53RE-134 MUT, 5′-CGGAAGGGAATCGCTTCGCGGTCGCTCGCGCTGCGCCGG-3′) were generated using an oligonucleotide synthesizer (IDT DNA Technologies). For competition electrophoretic mobility shift assay (EMSA), 100-fold (4 pmol) excess of unlabeled double-stranded probe was added to the binding reaction. Detailed procedures for EMSA assay can be found in [Supplemental Experimental Procedures](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1).

RNA EMSA
--------

TTP binding to *Lin28* mRNA 3′-UTR was determined by RNA EMSA as described previously ([@gkt222-B21]). Briefly, cytoplasmic extracts were prepared from DOX-treated PA1 cells using NE-PER nuclear and cytoplasmic extraction reagents (Thermo Pierce Biotechnology Scientific, Rockford, IL). EMSAs were performed using biotinylated RNA probes ([@gkt222-B21]) and the LightShift™ Chemiluminescent EMSA kit (Thermo Pierce Biotechnology Scientific). Anti-TTP antibody (T5327, Sigma) and control antibody (I-5381, Sigma) were used for RNA EMSA supershift.

Chromatin immunoprecipitation assay
-----------------------------------

Chromatin immunoprecipitation (ChIP) assays were performed using the EZ-Magna ChIP™ G Kit (Millipore) according to the manufacturer's instructions. The nuclei were isolated from cells. Isolated nuclei were sonicated to shear the DNA (average fragment size was 500 bp), and chromatin was immunoprecipitated with anti-p53 antibody or isotype control. The complexes were collected on protein-G-Magnetic beads and subsequently extracted from the beads. Bound DNA was purified and amplified by PCR with primers: TTPp primers (5′-GCCCAGGGCCGGGCGGAA-3′ and 5′-AGGAAACTGCAAGCACGG-3′), which amplified the 130-bp region (−157 to −28) of the TTP promoter containing target p53 motifs; p21p primers (5′-CTGGACTGGGCACTCTTGTC-3′ and 5′-CTCCTACCATCCCCTTCCTC-3′), which amplified the 214-bp region (−2376 to −2163) of the p21 promoter containing target p53 motif.

SDS--PAGE analysis and immunoblotting
-------------------------------------

Proteins were resolved by SDS--PAGE, transferred onto Hybond-P membranes (Amersham Biosciences Inc.) and probed with appropriate dilutions of the following antibodies: rabbit anti-human TTP (T5327, Sigma), anti-human Lin28a (ab46020, Abcam), anti-p53 (1026-1, Epitomics), anti-phospho-p53 (\#9284, Cell Signaling), anti-p21 (2990-1, Epitomics), anti-caspase-3 (sc-7272, Santa Cruz) and anti-β-actin (A2228, Sigma). Immunoreactivity was detected using the ECL detection system (Amersham Biosciences Inc.). Films were exposed at multiple time points to ensure that the images were not saturated.

RNA kinetics, quantitative real-time PCR and semi-qRT-PCR
---------------------------------------------------------

For RNA kinetic analysis, we used actinomycin D and assessed TTP mRNA expression by quantitative real-time PCR (qRT-PCR). DNase I-treated total RNA (3 µg) was reverse transcribed using oligo-dT and Superscript II reverse transcriptase (Invitrogen) according to the manufacturer's instructions. qRT-PCR was performed by monitoring in real-time the increase in fluorescence of SYBR Green dye (QIAGEN, Hilden, Germany) using StepOnePlus™ real-time PCR systems (Applied Biosystems). Semi-qRT-PCR was performed using Taq polymerase (Solgent, Daejeon, Korea) and PCR primer pairs ([Table S1](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1)).

miRNA analysis
--------------

Total RNA was isolated with Trizol reagent (Ambion). Quantitative levels of mature *let-7 b* and *let-7f* were determined using TaqMan® MicroRNA Assay kits (let-7 b-002619 and let-7f-000382, Applied Biosystems) according to the manufacturer's protocol. Mature miRNAs were detected using StepOne Plus by monitoring in real-time the increase in fluorescence of TaqMan probe-based detection (Applied Biosystem).

Statistical analysis
--------------------

Differences in the expression of TTP and p53 among clinicopathological groups were evaluated by the Student's *t*-test. A *P* value of \<0.05 was considered statistically significant.

RESULTS
=======

*TTP* expression is induced by DOX in a p53-dependent manner
------------------------------------------------------------

A search for transcription factor--binding sites within the *TTP* promoter region using online software (MatInspector) revealed the presence of three potential p53 half-sites. We first determined the involvement of p53 in *TTP* expression by measuring *TTP* levels after treatment with the DNA-damaging agent DOX, a potent p53 inducer, in the *p53* wild-type PA1 human ovarian cancer cell line. DOX treatment increased the levels of total and phosphorylated p53 proteins in a time-dependent manner ([Figure 1](#gkt222-F1){ref-type="fig"}A). We found that exposure to DOX increased not only a known p53 target, p21, but also both TTP protein and mRNA levels ([Figure 1](#gkt222-F1){ref-type="fig"}A and B). We also confirmed that DOX treatment increased *TTP* levels in a dose-dependent manner ([Figure 1](#gkt222-F1){ref-type="fig"}C). The levels of *TTP* transcript and protein were also increased in p53 wild-type MCF7 human breast cancer cells ([Supplementary Figure S1A--C](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1)) and *p53* wild-type Colo205 human colon cancer cells ([Supplementary Figure S2A](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1) and [B](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1)) after DOX treatment. To determine whether TTP can be induced by other DNA-damaging agents, MCF7 cells were treated with 0.1 μg/ml 5-FU or 50 μM etoposide for 24 h and analyzed for the levels of p53, p21 and TTP. They increased both TTP protein and mRNA levels ([Supplementary Figure S3](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1)), indicating that induction of TTP is a global response to DNA damage. Figure 1.DOX induces expression of *TTP* mRNA and protein by a p53-dependent mechanism in human cancer cells. (**A--C**) DOX increases TTP levels in p53 wild-type human ovarian cancer PA1 cells. PA1 cells were treated with the indicated concentration of DOX for (A) the indicated length of time or (B, C) 24 h. The levels of *TTP*, p53 and p21 were measured by semi-qRT-PCR (A and C, top), qRT-PCR (B) and western blotting (A and C, bottom). The level of phospho-p53 (pp53) was measured by western blotting (A, bottom). Values are means ± SD (*n* = 3). \*\*\**P* \< 0.001. (**D--G**) p53 is required for DOX-induced expression of TTP. (D, E) p53 mutant human ovarian cancer NIH:OVCAR3 cells were treated with the indicated concentration of DOX for 24 h. The level of TTP was measured by semi-qRT-PCR (D, top), qRT-PCR (E) and western blotting (D, bottom). Vaules are means ± SD (*n* = 3). ns, not significant. (F) NIH:OVCAR3 cells were transfected with pCMV-p53WT. After treatment with 0.3 μg/ml of DOX for 24 h, the levels of TTP, p53 and p21 were measured by semi-qRT PCR (top) and western blotting (bottom). (G) PA1 cells were transfected with siRNA against p53 (p53-siRNA) or scRNA. After treatment with DOX for 24 h, the levels of TTP, p53, and p21 were measured by semi-qRT PCR (top) and western blotting (bottom). (**H**) The level of TTP protein is inversely correlated with that of p53 protein in several human cell lines. Levels of TTP and p53 proteins were determined by western blot analysis in lung adenocarcinoma (A549 and H1299), hepatocellular carcinoma (HepG2 and Hep3B), gastric adenocarcinoma (AGS, SNU16, SNU668 and SNU750), colon adenocarcinoma (Colo205, HCT116, HT29 and SW480). WT, p53 wild type; Mut, p53 mutant. (**I**) TTP expression levels are inversely correlated with that of mutant p53 in human colon tissues. Representative immunohistochemical staining of TTP and mutant p53 in normal and colon adenocarcinoma tissues.

To investigate whether DOX-induced expression of *TTP* is functionally dependent on p53, we measured *TTP* levels in *p53* mutant human cancer cells such as NIH:OVCAR3 human ovarian cancer cells and MDA-MB231 human breast cancer cells after DOX treatment. In both NIH:OVCAR3 ([Figure 1](#gkt222-F1){ref-type="fig"}D--F) and MDA-MB231 cells ([Supplementary Figure S1D--F](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1)), DOX treatment did not significantly increase the levels of *p53*, *p21* or *TTP*. To further confirm the involvement of p53 in DOX-induced expression of *TTP*, we examined the effect of silencing endogenous p53 using siRNA on *TTP* expression induced by DOX in PA1, MCF7 and Colo205 cells. Down-regulation of *p53* significantly attenuated the expression of *TTP* transcript and protein induced by DOX ([Figure 1](#gkt222-F1){ref-type="fig"}G, [Supplementary Figure S1G](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1) and [S2C](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1)). We next transfected NIH:OVCAR3 and MDA-MB231 cells with pCMV-p53WT to overexpress wild-type *p53*. DOX treatment of NIH:OVCAR3 and MDA-MB231 cells together with ectopic expression of wild-type *p53* increased the levels of TTP transcript and protein ([Figure 1](#gkt222-F1){ref-type="fig"}F and [Supplementary Figure S1F](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1)). These data indicate that the human *TTP* promoter is under positive regulation by p53 in cancer cells.

Expression of TTP is inversely correlated with p53 mutations in human cancer cell lines and colonic adenocarcinoma tissues
--------------------------------------------------------------------------------------------------------------------------

To determine the relationship between *p53* mutations and TTP expression, we analyzed the expression of TTP in six *p53* wild-type (A549, HepG2, AGS, SNU16, Colo205 and HCT116) and six *p53* mutant (H1299, Hep3B, SNU668, SNU750, HT29 and SW480) human cancer cell lines. While cell lines with wild-type *p53* showed high expression levels of TTP, those with mutant *p53* showed a low level of TTP ([Figure 1](#gkt222-F1){ref-type="fig"}H), suggesting a negative correlation between *p53* mutations and TTP expression in human cancer cell lines. To evaluate the contribution of *p53* in TTP expression in *p53* wild-type cancer cells, we determine the effect of *p53* down-regulation on the TTP expression level in *p53* wild-type MCF7 cells. Knock-down of *p53* by siRNA treatment decreased TTP level ([Supplementary Figure S4A](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1)), indicating that TTP expression in *p53* wild-type cancer cells dependents on *p53*. TTP expression has been reported to be decreased in many tumor types ([@gkt222-B22]). To compare the TTP expression levels in Colo205 and HCT116 colon cancer cells with those in human normal colonic mucosa, we conducted western blotting. The TTP levels in both Colo205 and HCT116 were lower than those in normal tissues ([Supplementary Figure S4B](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1)). We next determined whether TTP protein expressed in cancer cells is active in promoting mRNA decay. A549 (with high TTP level) and H1299 (with low TTP level) cells were transfected with a luciferase reporter gene linked to 3′-UTR fragments of *Lin28a*, a TTP target gene ([@gkt222-B21]). The luciferase activity in A549 cells was significantly lower than that in H1299 cells ([Supplementary Figure S5](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1)). *TTP* knock-down by siRNA treatment significantly increased the luciferase activity in A549 cells ([Supplementary Figure S5](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1)), indicating that TTP in p53 wild-type cancer cells is active.

It has been reported that missense mutations of *p53* increase its stability and high levels of p53 correlate with *p53* mutations in tumor samples ([@gkt222-B23]). To determine the correlation between *p53* mutations and TTP expression, we examined the expression of p53 and TTP proteins in 45 colonic adenocarcinoma tissues by immunohistochemical staining. Forty-eight normal colonic mucosa tissues distant from the cancer of the surgically resected specimens were used as normal controls. p53 expression was extremely low in normal mucosa (mean staining score, 0.65 ± 0.14) and high in colon cancer (mean staining score, 9.00 ± 0.64) (*P* \< 0.0001) ([Figure 1](#gkt222-F1){ref-type="fig"}I, [Table 1](#gkt222-T1){ref-type="table"}). In contrast, expression of TTP was significantly low in colon cancer (mean staining score, 2.29 ± 0.31) but high in non-malignant tissues (mean staining score, 8.35 ± 0.37) (*P* \< 0.0001; [Figure 1](#gkt222-F1){ref-type="fig"}I and [Table 1](#gkt222-T1){ref-type="table"}). These results suggest that the expression level of TTP is inversely correlated with expression of p53 in colon carcinoma. Table 1.TTP and p53 expression and clinicopathologic features of patients with colon cancersDisease index*n*p53TTPStaining score^a^*P* valueStaining score^a^*P* valueTumor459.00 ± 0.64\<0.00012.29 ± 0.31\<0.0001Normal mucosa480.65 ± 0.148.35 ± 0.37[^2]

p53 stimulated by DOX enhances *TTP* promoter activity
------------------------------------------------------

The experiments above indicated that DOX was able to induce *TTP* transcription and its induction was p53-dependent. We first determined whether DOX treatment affects the *TTP* mRNA stability. As shown in [Supplementary Figure S6](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1), *TTP* mRNA stability was not affected by DOX treatment, suggesting that DOX-induced expression of *TTP* does not result from the increase in the *TTP* mRNA stability. We next tested whether DOX treatment transactivates the *TTP* promoter in a reporter assay. The *p53* wild-type PA1 cells were transiently transfected with pGL3/TTPp-1343 construct (−1343 to +68) containing three potential p53 half-sites of the human *TTP* gene ([Figure 2](#gkt222-F2){ref-type="fig"}A) followed by treatment with DOX. As shown in [Figure 2](#gkt222-F2){ref-type="fig"}B, DOX treatment significantly increased *TTP* promoter activity in a dose-dependent manner in PA1 cells at 6 h after the treatment. To confirm the involvement of p53 in DOX-induced activation of the *TTP* promoter, we inhibited *p53* expression in PA1 cells using siRNA. Down-regulation of *p53* by siRNA ([Figure 1](#gkt222-F1){ref-type="fig"}G) abrogated DOX induction of the *TTP* promoter in PA1 cells ([Figure 2](#gkt222-F2){ref-type="fig"}B). Coinciding with this result, DOX treatment did not stimulate the *TTP* promoter in *p53* mutant NIH:OVCAR3 cells ([Figure 2](#gkt222-F2){ref-type="fig"}C). We next transfected NIH:OVCAR3 cells with pCMV-p53WT to overexpress wild-type *p53*. DOX treatment of NIH:OVCAR3 cells together with ectopic expression of wild-type *p53* increased *TTP* promoter activity ([Figure 2](#gkt222-F2){ref-type="fig"}C). These data indicate that the human *TTP* promoter is under positive regulation by p53 in human cancer cells. Figure 2.DOX induces *TTP* promoter activity in a p53-dependent manner. (**A**) Schematic structure of the reporter construct pGL3/TTPp-1343. The TTP promoter contains three potential p53 half-sites at positions −771, −175 and −134 relative to the transcription start site. (**B, C**) DOX induces TTP promoter activity in a p53-dependent manner. (B) PA1 cells were co-transfected with pGL3/TTPp-1343 containing the *TTP* promoter (−1343 to +68) and p53-siRNA or scRNA. (C) NIH:OVCAR3 cells were co-transfected with pGL3/TTPp-1343 and pCMV-p53WT (p53 wild type) or pCMV-p53MUT (p53 mutant). After treatment with DOX for 24 h, luciferase activity was measured. The expression levels obtained from pGL3/TTPp-1343-transfected cells without DOX treatment were set to 1. Values are means ± SD (*n* = 3). \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. (**D, E**) p53 half-site at −134 relative to the transcription start site is required for the transcriptional activation of the TTP promoter. (D) Deletion and (E) mutation analysis of the *TTP* promoter in NIH:OVCAR3 cells. Schematic structures of the deletion and point mutation reporter constructs are shown on the left. Three potential p53 half-sites are indicated with open circles. The point mutations introduced into the binding sites are represented as closed circles. NIH:OVACAR3 cells were co-transfected with the TTP promoter construct and pCMV-p53WT or pCMV-p53MUT. After treatment with DOX for 24 h, cells were lysed and assayed for luciferase activity. The levels of firefly luciferase activity were normalized to *Renilla* luciferase activity. The expression levels obtained from pGL3 basic-transfected cells were set to 1. Values are means ± SD (*n* = 3). \*\**P* \< 0.01; \*\*\**P* \< 0.001.

p53 half-site at −134 is responsible for DOX-inducible promoter activity
------------------------------------------------------------------------

To evaluate the contribution of three potential p53 half-sites (5′-RRR[CWWG]{.ul}YYY-3′; positions −771, −175 and −134 relative to the transcription start site) ([Figure 2](#gkt222-F2){ref-type="fig"}A) in the regulation of *TTP* promoter activity by DOX, a series of deletion constructs were prepared by inserting different fragments of the human *TTP* promoter with a fixed 3′-end at the +68 position (relative to the transcription start site) but a different 5′-end into the pGL3-Basic vector. NIH:OVCAR3 cells were co-transfected with the *TTP* promoter construct and pCMV-p53WT or pCMV-p53MUT, and promoter activity was assessed by measuring luciferase activity after DOX treatment. While DOX induced luciferase levels in cells transfected with pCMV-p53WT, it did not in cells transfected with pCMV-p53MUT ([Figure 2](#gkt222-F2){ref-type="fig"}D). As shown in [Figure 2](#gkt222-F2){ref-type="fig"}D, deletion from −1343 to −211 (pGL3/TTPp-211) did not reduce luciferase levels. However, further deletion from −211 to −41 (pGL3/TTPp-41) dramatically reduced luciferase levels to \<5% of those of the parental construct pGL3/TTPp-1343, suggesting the presence of a positive regulatory element in this region. This region contains two potential p53 half-sites (positions −175 and −134 relative to the transcription start site) ([Figure 2](#gkt222-F2){ref-type="fig"}D). To evaluate the contribution of these two potential p53 half-sites in the regulation of *TTP* promoter activity by DOX, we made point mutations of them in the context of the reporter construct pGL3/TTPp-211, and mutant promoter activity was compared with that of the wild-type promoter. Mutation of the first p53 half-site (−175) (pGL3/TTPp-211/-175MUT) did not reduce the ability of DOX to activate transcription through this promoter ([Figure 2](#gkt222-F2){ref-type="fig"}E). However, mutation of the second p53 half-site (−134) (pGL3/TTPp-211/-134MUT) completely abrogated DOX-mediated promoter induction in PA1 null cells ([Figuer 2](#gkt222-F2){ref-type="fig"}E). These results indicate that the p53 half-site at −134 plays important role in DOX induction of *TTP* promoter activity.

DOX enhances binding of p53 to the *TTP* promoter
-------------------------------------------------

To determine the nature of the interaction of p53 with the p53 half-site at −134 in the *TTP* promoter, we performed an EMSA in PA1 cells using a 23-bp oligonucleotide bearing the wild-type or mutant p53 half-site at −134 as a probe. When EMSA was conducted using the wild-type *p53* probe, a dominant DNA--protein complex was observed, and DOX significantly increased the intensity of the DNA--protein complexes ([Figure 3](#gkt222-F3){ref-type="fig"}A, lanes 3 and 4). However, the mutant *p53* probe prevented formation of this complex ([Figure 3](#gkt222-F3){ref-type="fig"}A, lanes 1 and 2). The complex competed with an excess of the unlabeled wild-type *p53* probe but did not with unlabeled mutant *p53* probe ([Figure 3](#gkt222-F3){ref-type="fig"}B), demonstrating that these DNA--protein complexes are p53 site specific. The DNA--protein complexes were dramatically reduced in a dose-dependent manner by preincubation of the reaction mixture with an anti-p53 antibody ([Figure 3](#gkt222-F3){ref-type="fig"}A, lanes 5 and 6). However, preincubation of the reaction mixture with an isotype control did not reduce the complexes ([Figure 3](#gkt222-F3){ref-type="fig"}A, lane 7). These results indicate that p53 can specifically interact with the p53 half-site at −134, and DOX increases this interaction. To confirm the direct binding of p53 to the *TTP* promoter *in vivo*, we performed a ChIP assay in PA1 cells treated with DOX. As a positive control, we determined the binding of p53 to the promoter of *p21*, a well-known *p53* target gene. Chromatin was sonicated into fragments and precipitated using an anti-p53 or isotype control antibody. The precipitated DNA was subjected to PCR using primers designed to amplify a 130-bp fragment of the *TTP* promoter flanking the p53 half-site at −134 or a 214-bp fragment of the p21 promoter. In the absence of DOX, a significant level of p53 was found to be bound to the promoters of both *p21* and *TTP* in the absence of DOX. DOX treatment significantly increased p53 binding to the promoter of both genes ([Figure 3](#gkt222-F3){ref-type="fig"}C, [Supplementary Figure S7](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1)). This result indicates that DOX treatment increases recruitment of p53 to the *TTP* promoter in living cells. Figure 3.DOX enhances binding of p53 to the *TTP* promoter. (**A, B**) EMSA and (**C**) ChIP assay. PA1 cells were treated with DOX for 24 h. (A) EMSA was performed as described in Experimental Procedures. Biotinylated oligonucleotide containing wild-type (WT) or mutant (MUT) p53 half-site at −134 of the TTP promoter was used as a probe. To identify p53 immunoreactivity in the DNA--protein complexes, nuclear extracts were incubated with anti-p53 antibody or non-specific mouse IgG before addition of the biotinylated probe. An arrow indicates the position of the DNA--protein complexes containing p53. (B) Competition experiments were performed using a 100-fold excess of unlabeled WT and MUT *p53* probes. (C) ChIP analysis was performed to confirm the interaction of *p53* with the *TTP* promoter *in vivo* in PA1 cells. Formaldehyde cross-linked chromatin from PA1 cells was incubated with anti-p53 antibody or with non-specific IgG. Total input DNA at a 1:10 dilution was used as positive control for the PCR reaction. Immunoprecipitated DNA was analyzed by PCR with primers specific for the *TTP* promoter.

TTP mediates the inhibitory effect of DOX on cell growth
--------------------------------------------------------

DOX treatment led to substantial inhibition (58% inhibition) of PA1 cell growth ([Figure 4](#gkt222-F4){ref-type="fig"}A). Our next goal was to determine whether TTP could mediate the growth inhibitory effect of DOX. We examined the effect of a *TTP* knock-down on DOX-induced inhibition of growth in PA1 cells. The treatment of siRNA against *TTP* (TTP-siRNA) significantly inhibited the expression of TTP in PA1 cells but showed a negligible effect on p53 and its target p21 ([Figure 4](#gkt222-F4){ref-type="fig"}B). Interestingly, TTP-siRNA but not scRNA attenuated the inhibitory effect of DOX on the growth of PA1 cells ([Figure 4](#gkt222-F4){ref-type="fig"}A). These results suggest that TTP is required for DOX-induced inhibition of PA1 cells. Figure 4.TTP mediates the inhibitory effect of DOX on cell growth. (**A, B**) Down-regulation of TTP by siRNA attenuates the inhibitory effect of DOX on cell growth. PA1 cells were transfected with TTP-specific (TTP-siRNA) or scRNA. After treatment with DOX for 24 h, (A) cell viability was assessed by measuring absorbance at 490 nm using a MTS cell proliferation assay and (B) the levels of TTP, p53, pp53 and p21 were measured by western blotting. The values obtained with mock-treated PA1 cells were set to 1. Values are means ± SD (*n* = 3). \*\*\**P* \< 0.001. (**C, D**) Down-regulation of TTP by siRNA does not affect DOX-induced apoptosis. PA1 cells were transfected with TTP-siRNA, p53-siRNA, scRNA), pcDNA3/Flag-Lin28a or pcDNA3/Flag. After treatment with DOX for 24 h, (C) the levels of procaspase-3 and caspase-3 were measured by western blotting. (D) Cells were labeled with an Annexin-V-FLUOS staining kit for quantitating cells undergoing apoptosis. Values are means ± SD (*n* = 3). \**P* \< 0.05. ns, not significant. (**E, F**) Down-regulation of TTP by siRNA alters the effect of DOX on the cell cycle. PA1 cells were transfected with TTP-siRNA, p53-siRNA or scRNA. (E) After treatment with DOX for 24 h, cells were stained with propidium iodide and cell cycle distribution and apoptotic DNA fragmentation (Sub-G1) were analyzed by flow cytometry. Data are representative of three independent experiments. R0, sub-G1; R1, G0/G1; R2, S; R3, G2/M. (F) Percentage of cells at each phase in different groups. (*n* = 3). \**P* \< 0.05. ns, not significant.

Several studies have shown that caspase-3 activation is required for induction of apoptosis in response to DOX ([@gkt222-B24]). Similar to previous reports, we also found that DOX activated caspase-3 in PA1 cells ([Figure 4](#gkt222-F4){ref-type="fig"}C). Next, we inhibited *TTP* expression by using siRNA against *TTP* and tested whether TTP is involved in DOX-induced caspase-3 activation. As shown in [Figure 4](#gkt222-F4){ref-type="fig"}C, while knock-down of *p53* blocked DOX-induced caspase-3 activity, the TTP knock-down did not affect caspase-3 activity. Consistently, while knock-down of p53 attenuated DOX-induced apoptosis, inhibition of TTP did not reduce the apoptosis ([Figure 4](#gkt222-F4){ref-type="fig"}D and E). This suggests that, while p53 mediates DOX-induced caspase-3 activation and apoptosis, TTP is not involved in caspase-3 activation and apoptosis.

DOX-induced p53 can inhibit cell proliferation through cell cycle arrest ([@gkt222-B25],[@gkt222-B26]). To determine the role of TTP in DOX-induced cell cycle arrest, we inhibited *TTP* expression in PA1 cells by using siRNA and analyzed the effect of *TTP* inhibition on DOX-induced cell cycle arrest. As a control, we used siRNA to also analyze the effect of *p53* inhibition on DOX-induced cell cycle arrest. DOX treatment increased the percentage of cells in S and G2/M phases ([Figure 4](#gkt222-F4){ref-type="fig"}E and F), indicating that DOX induces S and/or G2/M phase cell cycle arrest. Interestingly, a further increase of cells in S and G2/M phases was observed in cells treated with either p53-siRNA or TTP-siRNA ([Figure 4](#gkt222-F4){ref-type="fig"}E and F). The increase of cells in S and/or G2/M phase did not seem to result in an increase in cell cycle arrest because inhibition of *TTP* attenuated the growth inhibitory effect of DOX on cell proliferation ([Figure 4](#gkt222-F4){ref-type="fig"}A). This result suggests that TTP plays some role in regulating the cell cycle in DOX-treated cells.

DOX-induced expression of TTP down-regulates the expression of Lin28
--------------------------------------------------------------------

Previously, we reported that ectopic expression of TTP down-regulates the expression of *Lin28a* in PA1 cells ([@gkt222-B21]). Our next goal was to determine whether TTP induced by DOX can inhibit the expression of Lin28a. As shown in [Figure 5](#gkt222-F5){ref-type="fig"}A and B, DOX treatment decreased the expression of *Lin28a* confirmed by semi-qRT-PCR ([Figure 5](#gkt222-F5){ref-type="fig"}A, top), qRT-PCR ([Figure 5](#gkt222-F5){ref-type="fig"}B) and western blot ([Figure 5](#gkt222-F5){ref-type="fig"}A, bottom). To confirm the involvement of TTP in DOX-induced down-regulation of *Lin28a*, we inhibited *TTP* expression using siRNA and analyzed L*in28a* expression in DOX-treated PA1 cells. Down-regulation of *TTP* ([Figure 5](#gkt222-F5){ref-type="fig"}A) significantly attenuated the inhibitory effect of DOX on the expression of *Lin28a* transcript ([Figure 5](#gkt222-F5){ref-type="fig"}A and B) and protein ([Figure 5](#gkt222-F5){ref-type="fig"}A). In addition, treatment of siRNA against *p53* (p53-siRNA) abrogated the inhibitory effect of DOX on the expression of *Lin28a* transcript and protein ([Figure 5](#gkt222-F5){ref-type="fig"}D). This result suggests that TTP induced by DOX down-regulates *Lin28a* expression in PA1 cells. TTP has been reported to down-regulate *Lin28a* expression by binding to the 3′-UTR of *Lin28a* mRNA ([@gkt222-B21]). To determine whether down-regulation of *Lin28a* expression by DOX-induced TTP is mediated through the 3′-UTR of *Lin28a* mRNA, we used a luciferase reporter gene linked to *Lin28a* 3′-UTR fragments containing pentameric AUUUA in the plasmid psiCHECK2 ([@gkt222-B21]). When PA1 cells were treated with DOX to induce TTP expression ([Figure 5](#gkt222-F5){ref-type="fig"}A), luciferase activity was inhibited ([Figure 5](#gkt222-F5){ref-type="fig"}C). The inhibitory effect of DOX on luciferase activity was attenuated by knock-down of *TTP* ([Figure 5](#gkt222-F5){ref-type="fig"}C). To test whether DOX increases TTP binding to *Lin28a* mRNA 3′-UTR, we performed RNA EMSA using the RNA probes as described previously ([@gkt222-B21]). As shown in [Supplementary Figure S8](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1), wild-type *Lin28a* 3′-UTR probe (Lin28 WT probe) formed probe--protein complexes and DOX treatment increased the level of the complexes. The formation of the complexes was reduced by preincubation of the reaction mixture with anti-TTP antibody ([Supplementary Figure S8](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1)). Taken together, these data indicate that the 3′-UTR of *Lin28a* mRNA is responsible for down-regulation of *Lin28a* by DOX-induced TTP. Figure 5.DOX increases *let-7* levels through the p53-TTP-Lin28 pathway. (**A--C**) DOX decreases Lin28 levels in a TTP-dependent manner. (A, B) PA1 cells were transfected with TTP-siRNA or scRNA. After treatment with DOX for 24 h, the levels of TTP and Lin28a were measured by semi-qRT-PCR (A, top), western blotting (A, bottom) and qRT-PCR (B). Values are means ± SD (*n* = 3). \**P* \< 0.05. (C) PA1 cells were co-transfected with psiCHECK2 luciferase reporter constructs containing fragments derived from the 3′-UTR of *Lin28a* mRNA and TTP-siRNA or scRNA. After treatment with DOX for 24 h, cells were lysed and assayed for luciferase activity. The levels of firefly luciferase activity were normalized to *Renilla* luciferase activity. Luciferase activity obtained from PA1 cells transfected with psiCHECK2 alone was set to 1.0. Values are means ± SD (*n* = 3). \*\*\**P* \< 0.001. (**D--G**) DOX increases let-7 levels through the p53-TTP-Lin28 pathway. (D, E) PA1 cells were transfected with TTP-siRNA, p53-siRNA, or scRNA. After treatment with DOX for 24 h, (D) the levels of TTP, p53, Lin28, HMGA2, and CDC34 were measured by semi-qRT-PCR (top) and western blotting (bottom) and (E) the levels of mature-miRNA for *let-7 b* and *let-7f* were determined by qRT-PCR. The levels obtained from untreated PA1 cells were set to 1. Values are means ± SD (*n* = 3). \*\**P* \< 0.01. (F, G) PA1 cells were transfected with pcDNA3/Flag-Lin28a or pcDNA3/Flag. After treatment with DOX for 24 h, (F) the level of Lin-28 a was measured by semi-qRT-PCR (top panel) and western blotting (bottom panel) and the levels of mature-miRNA for *let-*7 b and *let-7f* were determined by qRT-PCR and (G) cell viability was assessed by measuring absorbance at 490 nm using a MTS cell proliferation assay. Values are means ± SD (*n* = 3). \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.

TTP mediates DOX-induced expression of let-7
--------------------------------------------

Overexpression of TTP has been reported to increase *let-7* levels through down-regulation of *Lin28a* ([@gkt222-B21]). We here examined the effect of DOX-induced TTP on *let-7* levels in PA1 cells. As shown in [Figure 5](#gkt222-F5){ref-type="fig"}E, DOX treatment increased the levels of *let-7 b* and *let-7f* and decreased the levels of *let-7* targets, *HMGA2* and *CDC34* ([Figure 5](#gkt222-F5){ref-type="fig"}D). To determine whether TTP mediates the increase of *let-7* levels in DOX-treated cells, we inhibited *TTP* expression using siRNA and analyzed *let-7* levels in DOX-treated PA1 cells. Inhibition of *TTP* significantly attenuated the effect of DOX on the expression of *let-7 b* and *let-7f*([Figure 5](#gkt222-F5){ref-type="fig"}E). Inhibition of *p53* by siRNA also blocked the increase of *let-7* in DOX-treated PA1 cells ([Figure 5](#gkt222-F5){ref-type="fig"}E). We next determined whether ectopic overexpression of *p53* in p53 null mutant cells shows the same effects on the expression of *Lin28* and *let-7* as DOX treatment. We transiently transfected SKOV3 cells (*p53* null mutant) with pCMV-p53WT and, after 24 h incubation, analyzed expression levels of *TTP*, *Lin28a* and *let-7*. As shown in [Supplementary Figure S9](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gkt222/-/DC1), similar to DOX treatment, overexpression of *p53* significantly increased the levels of *TTP* and *let-7* but decreased *Lin28a*. To determine if ectopic expression of *Lin28a* could block the DOX-induced increase in *let-7 b* levels, we transfected PA1 cells with pcDNA3/Flag-Lin28a, which does not contain the *Lin28a* 3′-UTR, and analyzed *let-7 b* levels and cell proliferation. Overexpression of *Lin28a* ([Figure 5](#gkt222-F5){ref-type="fig"}F) abrogated the effect of DOX on the expression of *let-7 b* ([Figure 5](#gkt222-F5){ref-type="fig"}F). In addition, overexpression of *Lin28a* blocked the inhibitory effect of DOX on PA1 cell growth ([Figure 5](#gkt222-F5){ref-type="fig"}G). Collectively, these results suggest that DOX increases *let-7* levels through the p53-TTP-Lin28 pathway.

DISCUSSION
==========

Previously we have reported that TTP increases *let-7* levels through down-regulation of the negative regulator Lin28 in cancer cells ([@gkt222-B21]). Both TTP and *let-7* can inhibit the growth of cancer cells through down-regulation of oncogenes ([@gkt222-B13],[@gkt222-B19],[@gkt222-B20]) However, a significant decrease in the expression of both TTP and *let-7* has been found in many cancer cells ([@gkt222-B13],[@gkt222-B22],[@gkt222-B27]). Until now, the mechanisms for the reduced expression of both TTP and *let-7* in cancer cells have not been clarified. Here, we demonstrated that p53 and p53 inducers such as DOX can act as key regulators for the expression of TTP and *let-7* in cancer cells. We first provided evidence that *TTP* is a target gene of p53: the *TTP* promoter region contains p53 responsible elements (REs); levels of *TTP* transcript and protein were increased by p53; p53 increased the expression of a luciferase reporter gene linked to a p53 RE from the *TTP* promoter; EMSA and ChIP analyses demonstrated that p53 binds to the p53 RE from the *TTP* promoter. We found that the DNA-damaging agent DOX also enhanced *TTP* levels. DOX is a widely used anticancer drug ([@gkt222-B28]) and has been reported to exert its inhibitory functions through p53-dependent and -independent pathways ([@gkt222-B29]). The induction of *TTP* by DOX seems to be mediated by the p53-dependent pathway because DOX did not enhance *TTP* levels in cells with *p53* mutations and inhibition of *p53* by using siRNA blocked the effect of DOX on *TTP* levels.

If p53 is the inducer of *TTP* expression in cancer cells, it is possible to speculate that TTP levels might be low in cells with *p53* mutations. In accordance with our expectations, TTP levels were low in cells with *p53* mutations compared with wild-type *p53* cells. We also determined the relationship between p53 and TTP levels in human colonic adenocarcinoma tissues. Approximately half of human cancers have inactivating mutations of p53, and most of the remaining tumors deactivate the p53 pathway ([@gkt222-B30]). Most mutant *p53* proteins produced by missense mutations are resistant to degradation and thus have prolonged half-lives, allowing their detection by immunohistochemical staining ([@gkt222-B23]). In the present study, immunohistochemical staining demonstrated a negative relationship between p53 and TTP expression. Thus, our results suggest that TTP levels are low in human tumor tissues with *p53* mutations, perhaps explaining the low TTP levels observed in most tumor tissues ([@gkt222-B22]).

Previously, we reported that TTP overexpression increases *let-7* levels through down-regulation of the negative regulator Lin28 ([@gkt222-B21]). In this study, we demonstrated that the DNA-damaging agent DOX induces the expression of *TTP* through p53 activation, suggesting the possibility that DOX may enhance *let-7* levels through the p53/TTP/Lin28 pathway in cancer cells. Here, we provided evidence supporting this hypothesis: DOX treatment decreased *Lin28a* levels; DOX treatment increased *let-7* levels and decreased *let-7* target genes, *HMGA2* and *CDC34*; inhibition of *p53* or *TTP* by siRNAs blocked the effect of DOX on the expression of *Lin28a*, *let-7*, *HMGA2* and *CDC34*; overexpression of *Lin28a* cDNA without the 3′-UTR blocked the effect of DOX on cell growth and expression of *let-7*, *HMGA2* and *CDC34*. It has been reported that p53 can increase the levels of miRNAs by enhancing transcription and/or processing of miRNAs: p53 activates transcription of the *miR-34*gene family, leading to production of miRNAs that promote apoptosis or senescence ([@gkt222-B8]); p53 interacts with the Drosha complex, facilitating the processing of a subset of pri-miRNAs to pre-miRNAs ([@gkt222-B11]). Our results uncover the existence of a novel p53/TTP/Lin28/let-7 pathway that links p53 activation with the expression of *let-7*. Mutational inactivation of p53 is frequently observed in various human cancers ([@gkt222-B30]), and our results provide an explanation for low levels of *let-7* in cancer cells ([@gkt222-B13]). Besides *let-7*, Lin28a can negatively regulate the expression of several other miRNAs such as *miR-107*, *miR-143* and *MiR-200C* ([@gkt222-B31]), raising the possibility that concerted up-regulation of several Lin28 target miRNAs by p53 may occur under certain physiological conditions. Further investigation will provide insights into how miRNAs are regulated by the p53-TTP-Lin28 pathway.

Recently it has been reported that *p21* mRNA contains ARE and TTP promotes its decay ([@gkt222-B32]). However, in this study, TTP down-regulated *Lin28a* expression without affecting the expression levels of *p21*. Our finding is consistent with other studies demonstrating the gene- and cell type-specific activity of TTP. In glioblastoma U87 cells, TTP was found to bind to the c-*myc* 3′-UTR and decay its mRNA ([@gkt222-B33]). However, in HeLa cells, although TTP enhanced the mRNA decay of granulocyte/macrophage colony-stimulating factor, interleukin-3, tumor necrosis factor-α, interleukin-2 and c-*fos*, it did not regulate the stability of c-*myc* mRNA ([@gkt222-B34]). In A549 cells, while TTP destabilized *LAT2* mRNA, it did not affect the stability of c-*fos* and c-*myc* ([@gkt222-B27]). It is not clear how TTP selectively regulates the stability of target mRNAs. Previously we have reported that the binding of TTP to the 3′-UTR of *cIAP2* mRNA is not enough for degradation of the target gene. Besides the sequences for TTP binding, additional nucleotide sequences are required for degradation of the target gene ([@gkt222-B35]). It is possible to speculate that TTP-mediated decay of mRNAs requires additional RNA-binding proteins with sequence- and cell type-specific activities. The possible candidates for the RNA-binding proteins are heterogeneous nuclear RNPs (hnRNPs). Approximately 30 hnRNPs have been identified and they have been reported to influence diverse cellular events, including transcription, splicing, polyadenylation, mRNA localization, translation and decay in sequence- and cell type--specific manner ([@gkt222-B36; @gkt222-B37; @gkt222-B38; @gkt222-B39]). One recent study suggested the possibility of association between TTP and hnRNP by demonstrating that transportin, which recognizes hnRNP A1, interacts with TTP and modulates TTP-mediated decay of ARE-containing mRNAs ([@gkt222-B40]). Further characterizing the other factors (especially hnRNPs) involved in TTP-mediated mediated mRNA decay will elucidate the molecular mechanisms of gene and cell type specificity of mRNA decay.

DOX induces G2/M phase cell cycle arrest ([@gkt222-B25],[@gkt222-B26]), caspase-3 activation ([@gkt222-B24]) and apoptosis ([@gkt222-B41]) in a p53-dependent manner. In this study, we found that DOX treatment induced caspase-3 activation, apoptosis and G2/M phase cell cycle arrest in PA1 cells. Inhibition of *p53* by siRNA attenuated the effects of DOX on both cell cycle arrest and apoptosis. Similar to previous reports, this finding suggests that activation of p53 is a key mechanism of action of DOX. Interestingly, inhibition of *TTP* by siRNA did not affect caspase-3 activation or apoptosis induced by DOX treatment but altered the inhibitory effect of DOX on cell cycle arrest. Our results indicate that induction of *TTP* is a key mechanism of action of p53 in mediating DOX-induced cell cycle arrest. Activation of p53 by various types of cellular stresses induces the expression of different subsets of p53 target genes, which leads to a range of cellular outcomes from cell recovery to cell death ([@gkt222-B42]). Besides DOX, other DNA-damaging agents may induce the expression of TTP in human cancer cells. However, it is not clear whether TTP induced by DNA-damaging agents other than DOX affects only the cell cycle and not apoptosis in cancer cells. Further study on the interaction between TTP, TTP target genes and p53 target genes will reveal the role of TTP in various types of cellular stresses and the mechanisms underlying how TTP mediates p53-induced cell cycle arrest.

In summary, multiple levels of evidence confirm that *TTP* is a direct target of p53 and mediates the inhibitory effect of DOX on cell proliferation through down-regulation of oncogenes and induction of the tumor suppressor *let-7*. This study provides a molecular mechanism for the reduced levels of both TTP and *let-7* in cancer cells reported to have various mutations of *p53*. In addition, the novel p53-TTP-Lin28-let-7 pathway expands our understanding of the cooperative network of tumor suppressor genes in cancer cells.
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